MX2021003475A - Metodos de purificacion de proteinas. - Google Patents

Metodos de purificacion de proteinas.

Info

Publication number
MX2021003475A
MX2021003475A MX2021003475A MX2021003475A MX2021003475A MX 2021003475 A MX2021003475 A MX 2021003475A MX 2021003475 A MX2021003475 A MX 2021003475A MX 2021003475 A MX2021003475 A MX 2021003475A MX 2021003475 A MX2021003475 A MX 2021003475A
Authority
MX
Mexico
Prior art keywords
protein purification
purification methods
proteins
solubilizable
solubilized
Prior art date
Application number
MX2021003475A
Other languages
English (en)
Inventor
Jia Liu
Melissa Patterson
Sean Mcclain
Original Assignee
Absci Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Absci Corp filed Critical Absci Corp
Publication of MX2021003475A publication Critical patent/MX2021003475A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/145—Extraction; Separation; Purification by extraction or solubilisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17002—Carboxypeptidase B (3.4.17.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

La presente invención proporciona métodos para purificar proteínas, que se expresan en forma de complejos solubilizables que producen proteínas activas y plegadas apropiadamente cuando se solubilizan. Otros aspectos de la invención se refieren a polipéptidos que pueden usarse en la expresión y purificación de proteínas.
MX2021003475A 2018-09-25 2019-09-25 Metodos de purificacion de proteinas. MX2021003475A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862735861P 2018-09-25 2018-09-25
PCT/US2019/052998 WO2020069011A1 (en) 2018-09-25 2019-09-25 Protein purification methods

Publications (1)

Publication Number Publication Date
MX2021003475A true MX2021003475A (es) 2021-09-10

Family

ID=68296636

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003475A MX2021003475A (es) 2018-09-25 2019-09-25 Metodos de purificacion de proteinas.

Country Status (11)

Country Link
US (2) US11584785B2 (es)
EP (1) EP3856760A1 (es)
JP (1) JP2022502039A (es)
KR (1) KR20210064325A (es)
CN (1) CN113286810A (es)
AU (1) AU2019349934A1 (es)
BR (1) BR112021005634A2 (es)
CA (1) CA3114395A1 (es)
IL (1) IL281804A (es)
MX (1) MX2021003475A (es)
WO (1) WO2020069011A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7170332B2 (ja) 2016-12-09 2022-11-14 アクストン バイオサイエンシズ コーポレーション インスリンとｆｃの融合物および使用方法
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
AU2019291945A1 (en) 2018-06-29 2021-01-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CN114846025A (zh) 2019-12-19 2022-08-02 阿卡斯通生物科学公司 超长效胰岛素-Fc融合蛋白及其使用方法
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
DK3972987T3 (da) 2020-04-10 2023-07-31 Akston Biosciences Corp Antigenspecifik immunterapi til COVID-19-fusionsproteiner og fremgangsmåder til anvendelse deraf
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
CN114903827B (zh) * 2022-05-07 2023-11-28 广东蒂姆森大健康科技有限公司 一种高稳定性的皂角水提物的制备方法
CN116046947B (zh) * 2023-01-28 2023-06-02 北京惠之衡生物科技有限公司 一种德谷胰岛素中残留赖氨酰内切酶的检测方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122014028365B8 (pt) 1999-06-25 2021-07-06 Genentech Inc artigo industrializado compreendendo um primeiro recipiente que compreende uma composição de humab4d5-8 nele contida e um segundo recipiente que compreende uma composição rhumab 2c4 nele contida
CN101535492A (zh) * 2005-02-11 2009-09-16 南加州大学 表达含有二硫键的蛋白质的方法
KR101589554B1 (ko) 2008-01-03 2016-02-01 코넬 리서치 파운데이션 인코포레이티드 원핵생물에서의 글리코실화 단백질 발현
WO2012115638A1 (en) * 2011-02-23 2012-08-30 Elona Biotechnologies Glargine proinsulin compositions and methods of producing glargine insulin analogs therefrom
WO2013168178A1 (en) * 2012-03-30 2013-11-14 Krishnan Archana Rajesh Process for renaturation of polypeptides
WO2017106583A1 (en) * 2015-12-15 2017-06-22 Absci, Llc Cytoplasmic expression system
CN104603274B (zh) 2012-08-05 2020-08-18 Absci有限责任公司 可诱导共表达系统
US20150353940A1 (en) 2013-08-05 2015-12-10 Absci, Llc Vectors for use in an inducible coexpression system

Also Published As

Publication number Publication date
US20230072673A1 (en) 2023-03-09
CA3114395A1 (en) 2020-04-02
IL281804A (en) 2021-05-31
EP3856760A1 (en) 2021-08-04
WO2020069011A1 (en) 2020-04-02
JP2022502039A (ja) 2022-01-11
US20200299343A1 (en) 2020-09-24
AU2019349934A1 (en) 2021-05-13
KR20210064325A (ko) 2021-06-02
BR112021005634A2 (pt) 2021-06-29
US11584785B2 (en) 2023-02-21
CN113286810A (zh) 2021-08-20

Similar Documents

Publication Publication Date Title
MX2021003475A (es) Metodos de purificacion de proteinas.
CY1124921T1 (el) Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων
MA40132A1 (fr) Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
EA201890278A1 (ru) Антитела к pd-l1
AU2015269210A8 (en) Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
MD3512543T2 (ro) Mutații de stabilizare a trimerului proteinei de înveliș HIV
MX2018011503A (es) Proteinas de union y metodos de uso de las mismas.
EA201491644A1 (ru) Фармацевтические композиции
WO2018187356A3 (en) Protein antigens and uses thereof
WO2015132675A3 (en) Methods and compositions for modifying the immune response
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
MX2021012047A (es) Polipeptidos de fusion de serpina y metodos para utilizar los mismos.
EP3543335A3 (en) Soluble intein fusion proteins and methods for purifying biomolecules
MX2022012042A (es) Composiciones de proteina anti-vegf y metodos para producir la misma.
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
MX2021001129A (es) Metodo de purificacion de antigenos.
CO2020016105A2 (es) Proteínas inmunodominantes y fragmentos en esclerosis múltiple
EA201792269A1 (ru) Полипептиды, нацеленные на слияние вич
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins
MX2016012428A (es) Aumento de la expresion de proteina recombinante con cobre.
NZ744289A (en) Composition containing amino acids
MX2020002552A (es) Métodos y composiciones para preparar proteína surfactante d (sp-d).
EP4249503A3 (en) Vsig8-based chimeric proteins